Business Context and Reporting Period
This Form 8-K was filed by AcelRx Pharmaceuticals, Inc. on August 13, 2012, reporting events occurring on August 9, 2012. The filing serves to announce the Company's financial results for the quarter ended June 30, 2012, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The filing explicitly references a press release (Exhibit 99.1) for these details but does not include the data within the body of this 8-K document.
Material Changes
No material changes or comparative financial data are detailed in the text of this filing. The document acts solely as a notification that results for the quarter ended June 30, 2012, have been issued.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It includes a standard disclaimer stating that the information in Item 2.02 and the accompanying press release is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other SEC filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 9, 2012) for actual financial figures and operational highlights.
- Verify the Company's name is AcelRx Pharmaceuticals, Inc. (Note: The request metadata listed "TALPHERA, INC.", which appears to be an error as the filing clearly identifies AcelRx).
- Confirm the reporting period is the quarter ended June 30, 2012.
- Note that this 8-K does not incorporate the financial data by reference into future filings.